Insider Selling: Iradimed Corp (NASDAQ:IRMD) VP Sells 2,000 Shares of Stock

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $20.92, for a total transaction of $41,840.00. Following the completion of the transaction, the vice president now directly owns 2,368 shares of the company’s stock, valued at approximately $49,538.56. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Brent Johnson also recently made the following trade(s):

  • On Wednesday, August 14th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $21.10, for a total transaction of $21,100.00.
  • On Monday, August 12th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $21.27, for a total transaction of $21,270.00.
  • On Friday, August 9th, Brent Johnson sold 2,400 shares of Iradimed stock. The shares were sold at an average price of $21.81, for a total transaction of $52,344.00.
  • On Monday, August 5th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $21.94, for a total transaction of $65,820.00.
  • On Wednesday, August 7th, Brent Johnson sold 7,000 shares of Iradimed stock. The stock was sold at an average price of $21.93, for a total transaction of $153,510.00.
  • On Friday, August 2nd, Brent Johnson sold 5,000 shares of Iradimed stock. The stock was sold at an average price of $22.83, for a total transaction of $114,150.00.
  • On Wednesday, July 31st, Brent Johnson sold 8,000 shares of Iradimed stock. The stock was sold at an average price of $22.68, for a total transaction of $181,440.00.
  • On Monday, July 1st, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.46, for a total transaction of $20,460.00.
  • On Wednesday, July 3rd, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $20.16, for a total transaction of $60,480.00.
  • On Friday, June 28th, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $20.53, for a total transaction of $41,060.00.

Shares of Iradimed stock traded down $0.14 during trading on Monday, hitting $20.99. 54,600 shares of the stock were exchanged, compared to its average volume of 70,388. The stock has a market cap of $238.66 million, a price-to-earnings ratio of 48.81 and a beta of 1.65. The firm’s 50-day moving average price is $20.04 and its 200 day moving average price is $23.58. Iradimed Corp has a 12-month low of $16.68 and a 12-month high of $38.78. The company has a debt-to-equity ratio of 0.06, a current ratio of 10.29 and a quick ratio of 9.39.



Several equities research analysts have recently issued reports on IRMD shares. BidaskClub cut shares of Iradimed from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. ValuEngine raised shares of Iradimed from a “sell” rating to a “hold” rating in a research report on Wednesday, July 31st. Finally, Zacks Investment Research cut shares of Iradimed from a “buy” rating to a “hold” rating in a research report on Wednesday, July 3rd. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $31.50.

Large investors have recently made changes to their positions in the stock. HM Payson & Co. acquired a new position in shares of Iradimed in the second quarter valued at approximately $89,000. Marshall Wace LLP raised its position in shares of Iradimed by 765.6% in the second quarter. Marshall Wace LLP now owns 74,416 shares of the medical equipment provider’s stock valued at $1,522,000 after buying an additional 65,819 shares during the last quarter. Morgan Stanley raised its position in shares of Iradimed by 14.3% in the second quarter. Morgan Stanley now owns 13,118 shares of the medical equipment provider’s stock valued at $268,000 after buying an additional 1,637 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Iradimed by 52.1% in the second quarter. AQR Capital Management LLC now owns 23,971 shares of the medical equipment provider’s stock valued at $490,000 after buying an additional 8,207 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Iradimed by 2.5% in the second quarter. Vanguard Group Inc. now owns 276,203 shares of the medical equipment provider’s stock valued at $5,649,000 after buying an additional 6,658 shares during the last quarter. Hedge funds and other institutional investors own 30.22% of the company’s stock.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Featured Story: Marijuana Stocks

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.